Category: 3. Business

  • Journal of Medical Internet Research

    Journal of Medical Internet Research

    Chronic respiratory diseases are major causes of global morbidity and mortality [,]. In 2019, chronic obstructive pulmonary disease (COPD), lung cancer, and lower respiratory infections ranked among the top 10 causes of disability-adjusted life-years for individuals older than 50 years []. Moreover, those with chronic respiratory diseases face additional challenges, including reduced quality of life and limited physical activity and exercise capacity [,].

    Pulmonary rehabilitation offers a comprehensive approach to improving physical and psychological well-being in people with chronic respiratory disease, incorporating exercise, behavior change, and education []. It has been shown to effectively enhance exercise capacity, quality of life, dyspnea, and even survival rates, especially in patients with COPD [-]. Muscle wasting and dysfunction, affecting both skeletal and respiratory muscles, are also common in these patients, alongside reduced physical activity and respiratory function [,]. Pulmonary rehabilitation, which includes intensive exercise training and nutritional support, may be the most effective intervention for such conditions [].

    Landmark studies have recommended pulmonary rehabilitation programs with exercise training sessions lasting 30-45 minutes per day, 3-5 days per week, for at least 8-12 weeks [,]. However, center-based programs often face barriers such as limited facilities, low awareness among health care providers, lack of patient motivation, minimal health insurance cost and social support, and transport challenges [-]. Moreover, it is also challenging for patients with chronic respiratory disease to maintain the rehabilitation programs in daily lives, as they did not receive sufficient instructions to continue their programs at home, resulting in insufficient participation and high dropout rates in center-based pulmonary rehabilitation [,,]. Consequently, alternatives to center-based rehabilitation are urgently needed [-]. The COVID-19 pandemic further accelerated the development of telerehabilitation alternatives to center-based pulmonary rehabilitation []. Thus, researchers have investigated the clinical efficacy of telerehabilitation compared with traditional face-to-face rehabilitation in individuals with COPD [-].

    Although telerehabilitation has been proposed previously, it encompasses several different models, including video conferencing, mobile apps, webpages, and audio or video telephone calls []. Among telerehabilitation modalities, the clinical evidence for smartphone app–based pulmonary rehabilitation remains inconclusive []. While such interventions have been shown to improve quality of life and alleviate respiratory symptoms, their effect on enhancing exercise capacity has been limited [-]. Notably, significant improvements in exercise capacity have been observed only among users with high adherence []. However, recent studies suggest that app-based rehabilitation programs are effective not only in maintaining physical activity but also in improving exercise capacity, highlighting their potential for future implementation in clinical practice [,]. Furthermore, pilot studies have suggested the potential of reducing hospital readmissions after COPD exacerbations compared with standard care [].

    In previous work, we reported positive outcomes in patients with chronic respiratory disease using a smartphone-based rehabilitation program in a single-arm prospective study []. In this study, we assessed the clinical efficacy of smartphone-based rehabilitation through a randomized controlled trial, with the study protocol being previously published []. Additionally, we conducted a feasibility trial (a single-arm prospective study) across 4 community primary health care clinics to evaluate whether an app-based rehabilitation program is feasible in primary health care facilities with limited medical resources. This study aimed to evaluate the clinical efficacy of smartphone app–based pulmonary rehabilitation programs in improving exercise capacity, quality of life, and respiratory symptoms in individuals with chronic respiratory diseases.

    Study Design

    This study adhered to the CONSORT statement () []. This single-center, single-blind randomized controlled trial was conducted at Asan Medical Center in Seoul, Republic of Korea. In 2023, a total of 90 participants were recruited from the pulmonology outpatient clinic and randomly assigned to the intervention or control group in a 2:1 ratio (60 in the intervention group and 30 in the control group). This 2:1 allocation strategy ensured that a larger number of participants were assigned to the intervention group, which helped maintain statistical power despite the potential for higher dropout rates in that group and allowed for more robust subgroup analyses. The initial plan was to include 81 participants (54 in the intervention group and 27 in the control group), based on an estimation for detecting significant improvement in maximal oxygen consumption (VO2 max) []; however, due to a higher-than-expected dropout rate, we ultimately enrolled 90 participants.

    The intervention lasted 12 weeks. The intervention group underwent app-based rehabilitation for 12 weeks. They received one protein supplement drink (Himmune Protein Balance Drink, 10 g protein per 190 mL pack, Ildong Foodis, Seoul, Republic of Korea) daily throughout the study period, as adequate protein intake was required during the rehabilitation program []. The control group received standard outpatient medical treatment without rehabilitation. Participants were assessed at baseline and again at the end of the 12-week rehabilitation period.

    A subsequent feasibility trial was conducted in 4 community primary health care clinics (Maseok Asan Clinic Internal Medicine, Seoul Comfort Medical Clinic, Good Breath Internal Medicine Clinic, and Seoul Eco Internal Medical Clinic). In 2023, 32 participants (different from the original randomized controlled trial participants) were recruited and underwent the 12-week app-based rehabilitation. They were assessed twice: at baseline and at the end of the program.

    Inclusion and Exclusion Criteria

    The inclusion criteria were as follows: (1) age of 20-80 years; (2) a dyspnea symptom score of ≥1 on the modified Medical Research Council (mMRC) dyspnea scale; and (3) a chronic respiratory disease, including (1) obstructive lung disease (such as asthma and COPD) with a forced expiratory volume in one second (FEV1) of <80% of the predicted value or FEV1/forced vital capacity (FVC) of <0.7, (2) bronchiectasis visible in more than one lung lobe on chest computed tomography, or (3) restrictive lung disease (such as tuberculous lung destruction or interstitial lung disease) with FVC or diffusing capacity for carbon monoxide (DLCO) of <80% of the predicted value [].

    The exclusion criteria were (1) disease exacerbation within 4 weeks before enrolment, (2) disabilities, (3) inability to use smartphone apps or being an iPhone user, (4) pregnancy or breastfeeding, (5) deemed unsuitable for participation by the attending physician, and (6) refusal to consent.

    Smartphone App and Rehabilitation Program

    The SENIORS smartphone app (LifeSemantics Corp, Seoul, Republic of Korea) was developed through collaboration with health care professionals, service designers, and software developer. It was built for Android devices (requiring Android 8.0 or later).

    The app included features such as exercise programs, exercise records, exercise partners, a 6-minute walk test, disease education specific to each respiratory disease, inhaler usage guidance, and a medication and health data diary. The pulmonary rehabilitation program consisted of 30 minutes of aerobic exercise (outdoor walking) and 20-30 minutes of limb and trunk muscle exercise. Smartphone sensors automatically track walking exercises without additional pedometers. The muscle exercise included warm-up stretching, a main exercise of varied muscle workouts with progressively increasing intensity (weekly), and cool-down stretching. Participants engaged in the rehabilitation program independently using the app, without intervention from the center site. The app displayed daily pop-up messages to encourage continued participation. Participants could earn incentives based on their exercise records (Figure S1 in ).

    Study Outcome

    The primary outcomes were VO2 max measured by cardiopulmonary exercise test [], and the COPD assessment test (CAT) []. Cardiopulmonary exercise test was conducted using an incremental protocol with a cycle ergometer (VIAsprint 150P; Carefusion) and a metabolic cart (Vmax 29; SensorMedics) []. To assess long-term rehabilitation effects, CAT scores for the intervention group were re-evaluated at 12 weeks post rehabilitation (24 weeks from baseline). The app was unavailable during the postrehabilitation period.

    Secondary outcomes included daily physical activity measured by the International Physical Activity Questionnaire Short Form (IPAQ) Korean Version [], mMRC dyspnea scale, quality of life questionnaires, such as EQ-5D-5L [,] and the Health-related Quality of Life Instrument with 8 Items (HINT-8) questionnaire [], lung function (FVC, FEV1, and DLCO), hand grip strength, and limb muscle mass measured by bioelectrical impedance analysis.

    The study outcomes were simplified in a feasibility study conducted in primary health care clinics. Primary outcomes were the 6-minute walk test distance and CAT [], and secondary outcomes included lung function (FVC and FEV1).

    Cost-Utility Analysis

    The main outcome indicators for the cost-utility analysis were the EQ-5D-5L and HINT-8 indexes, measured at baseline and the end of the intervention. Quality-adjusted life year (QALY) was calculated as the change in EQ-5D-5L or HINT-8 index from baseline to the end of the intervention for each participant []. Health care costs related to chronic respiratory diseases were gathered from invoices issued by Asan Medical Center, and outpatient drug costs were calculated based on prescription history. Based on the subscription costs of existing commercial applications, the app subscription fee in the intervention group was set at US $40 per month (approximately US $1=1400 Korean won as of November 2024), totaling US $120 for 3 months, with participant incentives deducted from this amount.

    Statistical Analysis

    Continuous variables were presented as medians with IQRs and compared using the Mann-Whitney U test (to compare the intervention and control groups at the same time point) or Wilcoxon signed-rank test (to compare baseline and follow-up within each group), as the number of participants was relatively small and most variables did not follow a normal distribution. A paired t test was conducted to evaluate the mean differences and corresponding CIs of normally distributed continuous variables (the CAT score and EQ-5D-5L index) before and after the intervention. Categorical variables were reported as numbers (percentages) and compared using the chi-square or Fisher exact test. All P values were 2-tailed, with statistical significance set at P<.05. All statistical analyses were conducted using SPSS (version 26.0; IBM SPSS Corp) and MedCalc Statistical Software (version 23.0.5; MedCalc Software Ltd).

    Ethical Considerations

    The study protocol was approved by the Institutional Review Board of Asan Medical Center (2022-1460) and the Public Institutional Review Board designated by the Ministry of Health and Welfare (P01-202303-01-013). This study adhered to the Declaration of Helsinki guidelines, and all procedures were conducted in compliance with relevant regulations. It was prospectively registered in the ClinicalTrials.gov database (NCT05610358). Written informed consent was obtained from all participants before inclusion. Participants were informed that their participation was voluntary and that they could withdraw from the study at any time without any disadvantage or penalty. All identifiable data were removed from the original dataset, and each participant was anonymized. Participants received small incentives (approximately US $30) based on their exercise records, which were obtained from the app’s log data for aerobic exercise timers and anaerobic exercise instruction videos. No identification of individual participants is possible in any images included in the manuscript or in Multimedia Appendices.

    Study Process and Baseline Characteristics

    shows the study process. Among 102 screened for eligibility, 90 participants were recruited and allocated to the intervention (n=60) and control (n=30) groups. Thereafter, 14 participants withdrew consents, one encountered a smartphone error, and 3 failed baseline studies. Consequently, 72 participants completed baseline assessments. In the intervention group, 47 participants began rehabilitation, and 46 completed follow-ups (included in the intention-to-treat analysis). Three were later identified as having no app-use history in log data, so 43 were included in the per-protocol analysis. In the control group, 25 began follow-up, with 24 completing it. Overall, 77.8% (70/90) of participants completed follow-ups, and no musculoskeletal injuries or disease exacerbations related to the rehabilitation program were reported.

    Figure 1. Study flowchart of a randomized controlled trial investigating the clinical efficacy of smartphone-based rehabilitation in individuals with chronic respiratory disease, conducted at Asan Medical Center, Seoul, Republic of Korea, 2023. ITT: intention to treat; PP: per protocol.

    presents the baseline characteristics of 70 participants who completed follow-ups. The median age was 65.5 years (IQR 61.0-72.0), with 48 (68.6%) men. Forty-four (62.9%) participants had a smoking history, and approximately three-quarters (53/70, 75.7%) had obstructive lung disease as their chronic respiratory disease.

    Table 1. Baseline characteristics of participants in a randomized controlled trial investigating the clinical efficacy of smartphone-based rehabilitation in individuals with chronic respiratory disease, conducted at Asan Medical Center, Seoul, Republic of Korea, 2023.
    Total (n=70) Intervention (n=46) Control (n=24) P value U value
    Age (years), median (IQR) 65.5 (61.0-72.0) 64.0 (60.0-68.0) 67.5 (62.5-74.5) .14 434.00
    Sex (male), n (%) 48 (68.6) 35 (76.1) 13 (54.2) .06 N/Aa
    Body weight (kg), median (IQR) 61.0 (54.0-71.4) 61.0 (54.0-71.8) 59.0 (53.0-70.2) .34 483.50
    Height (cm), median (IQR) 167.0 (160.0-172.0) 168.1 (161.0-172.0) 164.5 (157.0-168.0) .04 383.00
    BMI (kg/m2), median (IQR) 23.0 (20.0-25.4) 23.0 (19.8-25.3) 22.9 (20.8-25.6) .89 541.00
    Ever-smoker 44 (62.9) 32 (69.6) 12 (50.0) .11 N/A
    Respiratory disease, n (%) .29 N/A
    Obstructive 53 (75.7) 34 (73.9) 19 (79.2)
    Bronchiectasis 14 (20.0) 11 (23.9) 3 (12.5)
    Restrictive 3 (4.3) 1 (2.2) 2 (8.3)
    Comorbidities, n (%)
    Diabetes mellitus 9 (12.9) 5 (10.9) 4 (16.7) .48 N/A
    Hypertension 20 (28.6) 13 (28.3) 7 (29.2) .94 N/A
    Dyslipidemia 18 (25.7) 11 (23.9) 7 (29.2) .64 N/A
    Malignancy 6 (8.6) 2 (4.3) 4 (16.7) .17 N/A
    Lung resection 3 (4.3) 1 (2.2) 2 (8.3) .27 N/A

    aN/A: not applicable.

    Clinical Parameters of Participants

    In the per-protocol analysis, the baseline CAT score was higher in the intervention group than in the control group (median 16.0 vs 11.0, P=.08). At follow-up, the intervention group had a significantly lower CAT score than the control group (median 7.0 vs 10.0, P=.04). VO2 max did not significantly differ between groups at follow-up (median 14.0 vs 12.7 mL/kg/min, P=.24). The intervention group also showed significant improvements in the IPAQ score (median 1488.0 vs 1164.0, P=.04) and mMRC dyspnea scale (median 1.0 vs 2.0, P=.01) compared with the control group at follow-up (). In the intention-to-treat analysis, only the mMRC dyspnea scale showed a significant difference at follow-up, with no significant changes in the CAT score and IPAQ (Table S1 in ).

    Comparing clinical outcomes between baseline and follow-up in the intervention group, CAT score, IPAQ, mMRC dyspnea scale, EQ-5D-5L index, and HINT-8 index showed significant improvements, while these parameters, except for IPAQ, did not improve in the control group ( and Table S2 in ). In the intervention group, the CAT score showed a significant improvement from baseline to post-intervention (mean difference=–6.14, 95% CI –8.19 to –4.09, P<.001, t42=–6.051), exceeding the minimal important clinical difference of 2 points []. The EQ-5D-5L index demonstrated a meaningful increase (mean difference=0.073, 95% CI 0.042-0.103, P<.001, t42=4.814), surpassing the minimal important clinical difference for COPD (0.028) []. To assess long-term rehabilitation effects, the CAT score in the intervention group remained stable 12 weeks post-rehabilitation, showing no significant difference from the score at the end of rehabilitation (median 7.0 vs 8.0, P=.77, Figure S2 in ).

    Table 2. Comparison of clinical outcomes of participants between the intervention and control group (per protocol analysis) in a randomized controlled trial investigating the clinical efficacy of smartphone-based rehabilitation in individuals with chronic respiratory disease, conducted at Asan Medical Center, Seoul, Republic of Korea, 2023.
    Total (n=67), median (IQR) Intervention (n=43), median (IQR) Control (n=24) P value U value
    Baseline
    VO2 maxa (mL/kg/min, n=65) 15.3 (11.5-18.3) 15.7 (12.7-19.2) 13.4 (9.0-16.1) .06 339.50
    CATb score 14.0 (8.0-19.0) 16.0 (9.5-20.0) 11.0 (7.5-17.0) .08 380.50
    IPAQc (n=65) 693.0 (23.1-1535.3) 792.0 (26.0-1737.8) 445.5 (11.6-1188.0) .23 386.50
    mMRCd dyspnea scale 1.0 (1.0-2.0) 1.0 (1.0-2.0) 2.0 (1.0-2.0) .53 472.50
    EQ-5D-5L index 0.816 (0.752-0.862) 0.816 (0.743-0.861) 0.822 (0.777-1.000) .41 453.50
    HINT-8e index 0.804 (0.750-0.862) 0.792 (0.735-0.859) 0.811 (0.784-0.863) .16 409.00
    FEV1f (%predicted) 51.0 (42.5-65.8) 57.0 (44.3-66.8) 49.0 (38.5-56.0) .11 394.00
    FVCg (%predicted) 73.0 (66.3-87.5) 75.0 (66.3-87.5) 72.0 (64.0-86.0) .39 450.00
    DLCOh (%predicted) 58.0 (45.0-67.0) 61.0 (53.5-67.0) 50.0 (45.0-65.0) .30 436.00
    Hand grip strength (kg) 32.0 (25.7-39.2) 33.7 (28.0-41.0) 27.9 (21.5-37.1) .12 397.50
    Limb muscle mass (kg)
    Upper limb 4.8 (3.5-5.7) 5.0 (3.9-6.0) 4.3 (3.3-5.5) .06 371.00
    Lower limb 15.0 (12.4-16.8) 15.6 (13.1-17.0) 14.5 (10.8-15.6) .05 365.50
    Follow-up
    VO2 max (mL/kg/min, n=65) 12.9 (11.0-16.1) 14.0 (10.6-18.4) 12.7 (11.3-13.7) .24 389.00
    CAT score 8.0 (5.0-16.8) 7.0 (4.0-15.0) 10.0 (6.5-18.5) .04 358.50
    IPAQ (n=62) 1386.0 (876.0-2772.0) 1488.0 (1250.3-3027.8) 1164.0 (618.8-2205.0) .04 290.50
    mMRC dyspnea scale 1.0 (1.0-2.0) 1.0 (1.0-1.8) 2.0 (1.0-2.0) .01 346.50
    EQ-5D-5L index 0.862 (0.786-1.000) 0.871 (0.814-1.000) 0.829 (0.768-1.000) .22 425.50
    HINT-8 index 0.821 (0.751-0.876) 0.828 (0.767-0.891) 0.795 (0.728-0.848) .09 385.50
    FEV1 (%predicted) 50.0 (40.5-67.8) 58.0 (43.5-69.0) 45.0 (37.5-54.5) .06 372.00
    FVC (%predicted) 73.0 (67.3-87.5) 77.0 (69.3-87.5) 71.5 (63.0-86.0) .22 422.50
    DLCO (%predicted, n=66) 61.0 (49.0-71.0) 62.0 (51.0-71.8) 57.0 (48.0-64.8) .20 400.00
    Hand grip strength (kg) 32.7 (22.7-39.5) 33.3 (27.7-41.7) 24.0 (20.6-37.0) .08 380.00
    Limb muscle mass (kg)
    Upper limb 4.6 (3.6-5.9) 4.8 (3.8-6.1) 4.3 (3.5-5.5) .17 411.50
    Lower limb 15.0 (12.2-16.8) 15.4 (13.0-16.9) 14.4 (10.8-16.0) .08 381.00

    aVO2 max: maximal oxygen consumption. It was measured using a cardiopulmonary exercise test.

    bCAT: chronic obstructive pulmonary disease assessment test.

    cIPAQ: International Physical Activity Questionnaire.

    dmMRC: modified Medical Research Council.

    eHINT-8: Health-related Quality of Life Instrument with 8 Items.

    fFEV1: forced expiratory volume in one second.

    gFVC: forced vital capacity.

    hDLCO: diffusing capacity for carbon monoxide.

    Table 3. Comparison of clinical outcomes of participants between the baseline and follow-up (per protocol analysis) in a randomized controlled trial investigating the clinical efficacy of smartphone-based rehabilitation in individuals with chronic respiratory disease, conducted at Asan Medical Center, Seoul, Republic of Korea, 2023.
    Baseline, median (IQR) Follow-up, median (IQR) P value
    Intervention (n=43)
    VO2 maxa (mL/kg/min) 15.7 (12.7-19.2) 14.0 (10.6-18.4) .04
    CATb score 16.0 (9.5-20.0) 7.0 (4.0-15.0) <.001
    IPAQc (n=41) 792.0 (23.1-1649.3) 1488.0 (1250.3-3027.8) <.001
    mMRCd dyspnea scale 1.0 (1.0-2.0) 1.0 (1.0-1.8) .006
    EQ-5D-5L index 0.816 (0.743-0.861) 0.871 (0.814-1.000) <.001
    HINT-8e index 0.792 (0.735-0.859) 0.828 (0.767-0.891) <.001
    FEV1f (%predicted) 57.0 (44.3-66.8) 58.0 (43.5-69.0) .27
    FVCg (%predicted) 75.0 (66.3-87.5) 77.0 (69.3-87.5) .04
    DLCOh (%predicted) 61.0 (53.5-67.0) 62.0 (51.0-71.8) .08
    Hand grip strength (kg) 33.7 (28.0-41.0) 33.3 (27.7-41.7) .74
    Limb muscle mass (kg)
    Upper limb 5.0 (3.9-6.0) 4.8 (3.8-6.1) .47
    Lower limb 15.6 (13.1-17.0) 15.4 (13.0-16.9) .56
    Control (n=24)
    VO2 max (mL/kg/min, n=22) 13.4 (9.0-16.1) 12.7 (11.3-13.7) .45
    CAT score 11.0 (7.5-17.0) 10.0 (6.5-18.5) .78
    IPAQ (n=21) 198.0 (11.6-1237.5) 1164.0 (618.8-2205.0) .005
    mMRC dyspnea scale 2.0 (1.0-2.0) 2.0 (1.0-2.0) .74
    EQ-5D-5L index 0.822 (0.777-1.000) 0.829 (0.768-1.000) .26
    HINT-8 index 0.811 (0.784-0.863) 0.795 (0.728-0.848) .08
    FEV1 (%predicted) 49.0 (38.5-56.0) 45.0 (37.5-54.5) .46
    FVC (%predicted) 72.0 (64.0-86.0) 71.5 (63.0-86.0) .78
    DLCO (%predicted, n=23) 50.0 (45.0-65.0) 57.0 (48.0-64.8) .17
    Hand grip strength (kg) 27.9 (21.5-37.1) 24.0 (20.6-37.0) .29
    Limb muscle mass (kg)
    Upper limb 4.3 (3.3-5.5) 4.3 (3.5-5.5) .12
    Lower limb 14.5 (10.8-15.6) 14.4 (10.8-16.0) .67

    aVO2 max: maximal oxygen consumption. It was measured using a cardiopulmonary exercise test.

    bCAT: chronic obstructive pulmonary disease assessment test.

    cIPAQ: International Physical Activity Questionnaire.

    dmMRC: modified Medical Research Council.

    eHINT-8: Health-related Quality of Life Instrument with 8 Items.

    fFEV1: forced expiratory volume in one second.

    gFVC: forced vital capacity.

    hDLCO: diffusing capacity for carbon monoxide.

    The IPAQ questionnaire was administered during the cardiopulmonary exercise test, so these values were missing for the 2 participants with severely impaired lung function. Although some missing data (IPAQ and DLCO) were observed at the follow-up time point, the Little’s Missing Completely At Random test indicated that these data were missing completely at random (P=.12).

    Comparison of Clinical Parameters Among Subgroup Participants

    Defining physically active participants as those with an IPAQ score of >1000 at baseline, 19 participants in the intervention group were classified as physically active. At follow-up, their VO2 max (median 14.3 vs 12.7 mL/kg/min, P=.05) and IPAQ (median 2779.0 vs 1164.0, P=.009) were significantly higher than those of the participants in the control group. Their CAT score (median 5.0 vs 10.0, P=.005) and mMRC dyspnea scale (median 1.0 vs 2.0, P=.03) were also significantly lower than those of the participants in the control group. Comparing baseline and follow-up data, physically active participants in the intervention group showed significant improvements in the CAT score, EQ-5D-5L index, and HINT-8 index (Tables S3 and S4 in , ).

    Figure 2. Subgroup analysis: comparison of primary outcomes between participants in the intervention group (initially active, International Physical Activity Questionnaire > 1000) and the control group in a randomized controlled trial investigating the clinical efficacy of smartphone-based rehabilitation in individuals with chronic respiratory disease, conducted at Asan Medical Center, Seoul, Republic of Korea, 2023. Data are shown for (A) maximal oxygen consumption and (B) CAT score. CAT: chronic obstructive pulmonary disease assessment test; VO2 max: maximal oxygen consumption.

    Defining good compliance as completing > 50% of the assigned exercise program, 17 participants in the intervention group were classified as compliant. At baseline, their CAT scores were significantly higher than those of the participants in the control group. At follow-up, their CAT score did not significantly differ from that of the control group, but their IPAQ was significantly higher. Comparing baseline and follow-up data, compliant participants in the intervention group showed significant improvements in CAT score, EQ-5D-5L index, and HINT-8 index after the intervention (Tables S5 and S6 in ).

    Ease of Use of the App

    Among the user questionnaire of 43 participants who completed the rehabilitation program, approximately 80% (35/43) of participants in the intervention group found the app easy to use. More than 60% (27/43) felt it helped improve dyspnea symptoms. Additionally, 79.1% (34/43) expressed interest in using the app commercially, with 44.1% (15/34) noting that the exercise program tailored to their condition was its most attractive feature (Table S7 in ).

    Cost-Utility Analysis

    The mean hospital costs were US $300 for the control and US $250 for the intervention group. Outpatient drug costs averaged US $195 and US $189, respectively, while the app subscription fee averaged US $84 after incentive reductions. The mean total health care costs, including hospital, drug, and app fees, were US $495 in the control and US $523 in the intervention group. The QALY distribution using the EQ-5D-5L index was 0.208 for both groups, and using the HINT-8 index, it was 0.199 in the control and 0.201 in the intervention group ().

    Figure 3. Cost-utility analysis: distribution of total health care costs and quality-of-life utility between the intervention and control groups in a randomized controlled trial investigating the clinical efficacy of smartphone-based rehabilitation in individuals with chronic respiratory disease, conducted at Asan Medical Center, Seoul, Republic of Korea, 2023. Data are shown for (A) Euro-QoL 5-Dimension 5-Level index and (B) HINT-8 index. eQALY: the quality-adjusted life year calculated using the EQ-5D-5L; hQALY, the quality-adjusted life year calculated using the HINT-8 index.

    Feasibility Trial in Primary Health Care Clinics

    Subsequently, a feasibility trial was performed in primary health care clinics. Among 32 participants initially recruited, 24 completed follow-up visits (Table S8 in ). The median age was 62.5 years (IQR 57.0-69.0), with 58.3% (14/24) being men and 54.2% (13/24) having a smoking history (Table S9 in ). Comparing baseline to follow-up data, the CAT score significantly improved post rehabilitation (median 8.5 to 5.0, P<.001, Table S10 in ). No musculoskeletal injuries or disease exacerbations related to the rehabilitation program were reported.

    Principal Findings

    This study examined the clinical efficacy of a smartphone-based pulmonary rehabilitation program for patients with chronic respiratory diseases. It showed that the program improved the quality of life, daily physical activity, and dyspnea symptoms. Significant improvements were particularly notable in participants who were physically active or compliant with the exercise regimen, and positive outcomes were also observed in primary health care clinics. These findings suggest that smartphone-based pulmonary rehabilitation could be a valuable treatment option for older patients with chronic respiratory diseases.

    Improvements in Study Outcomes

    This program was associated with a significant improvement in the CAT score, which predicts the severity of airflow obstruction and disease exacerbation in patients with COPD [,]. The CAT score also correlates with lung function, 6-minute walk distance, and exertional desaturation in idiopathic pulmonary fibrosis and connective tissue disease-associated interstitial lung disease [,]. CAT also correlated with disease severity, lung function, and 6-minute walk distance in patients with bronchiectasis, making it a valid tool for this condition []. Although we included patients with a broad spectrum of chronic respiratory diseases, CAT score improvements may broadly predict clinical benefits. Notably, CAT scores in the intervention group remained stable 12 weeks post-rehabilitation, further supporting the program’s efficacy.

    Daily physical activity is crucial for patients with chronic respiratory disease, as low activity levels are linked to higher risks of acute exacerbation and mortality in COPD []. Patients with COPD generally have significantly reduced physical activity compared with healthy controls, though disease severity is not strongly correlated with activity levels []. Thus, even patients with severe COPD who stay active can reduce their exacerbation and mortality risks. This study found that physical activity improved through app-based pulmonary rehabilitation in older adults with chronic respiratory disease. Additionally, subgroup analysis showed marked clinical improvements in initially active participants, highlighting the importance of physical activity. Further studies with longer follow-ups could reveal reduced exacerbation and mortality rates from app-based rehabilitation.

    Compliance With Rehabilitation Programs

    As reported, compliance with home-based pulmonary rehabilitation remains a challenge []. In app-based rehabilitation, CAT scores were estimated to decrease by −0.22 (95% CI −0.74 to 0.31) per additional 7 days of app use []. However, while app use dropped from 85% in week one to 40% in the last week, active users maintained a consistent weekly usage of 4.9 days []. A previous study reported lack of motivation as the most common reason for nonadherence in home-based pulmonary rehabilitation, with non-adherent patients with COPD experiencing more exacerbations and reduced 6-minute walk distances []. In this study, 39.5% (17 of 43) of participants showed good compliance (completing >50% of assigned exercises) and demonstrated significant improvements in CAT scores and IPAQ. Thus, physicians should emphasize steady engagement with the app-based pulmonary rehabilitation program. The initial stage of pulmonary rehabilitation involves educating patients on how following an appropriate exercise program can improve their symptoms. Additionally, regular phone calls or text messages from health care providers can boost patient motivation []. Repeated exposure to exercise programs encourages app use and motivates patients to stay active.

    Cost-Utility Analysis

    In the cost-utility analysis, the mean health care costs were US $495 in the control group and US $523 in the intervention group. After reducing the app subscription fee (mean US $84 with incentive reductions), intervention group costs were US $439, notably lower than the control group. However, since the subscription fee was based on similar commercialized apps, it may be adjustable for future commercialization. While there was some cost difference between groups, QALYs based on EQ-5D-5L and HINT-8 indices were similar, limiting further cost-utility analysis. Previous cost-utility analyses have demonstrated that home-based pulmonary rehabilitation and tele-rehabilitation are more cost-effective compared with hospital-based pulmonary rehabilitation [,]. However, further studies are needed to evaluate the cost-effectiveness of these programs within the Korean health care context.

    Feasibility in Primary Clinics

    Pulmonary rehabilitation is typically provided in referral hospitals; however, primary care practitioners face barriers in referring patients with chronic respiratory diseases, including limited engagement from rehabilitation providers, patient’s poor physical ability or accessibility, low motivation, and unclear referral practices []. To address these issues, previous studies have delivered rehabilitation programs in primary care settings, reporting favorable outcomes in exercise capacity, quality of life, and dyspnea symptoms [,]. Our feasibility trial, conducted in a real-world setting, involved app-guided rehabilitation without provider education or guidance. Despite these limitations, we observed improvements in the CAT score and mMRC dyspnea scale, supporting the feasibility of app-based pulmonary rehabilitation in primary care, where center-based programs are generally unavailable.

    At an Australian referral center, the referral rate for pulmonary rehabilitation from primary care clinics was notably low—only 6% []. This likely reflects limited awareness and understanding of pulmonary rehabilitation among both patients and health care providers in primary care settings []. Considering the challenges many patients face in attending regular sessions at tertiary hospitals, as well as the impracticality of tertiary centers accommodating all eligible patients, there is a clear need to implement home-based rehabilitation programs. Using tools such as smartphone apps could enable continuous management of patients within primary care settings.

    Strengths, Limitations, and Future Perspectives

    This study has several notable strengths with innovative contributions to the field of digital pulmonary rehabilitation. First, unlike earlier mobile health interventions that targeted single diseases such as COPD or relied on simple video-based exercise guidance, the app offered integrated multidimensional components, incorporating exercise programs, disease education, medication management, social support, and a health data diary, in a single smartphone platform. Particularly, exercise levels could be adjusted according to exercise performance records. The app included social support features that allowed users to see their ranking by comparing their exercise records with those of other users, as well as send and receive encouraging messages with one another. Second, the program was validated not only in a tertiary hospital setting but also through a feasibility trial in primary care clinics, highlighting its scalability and adaptability for community-level implementation. Third, it was quite a novel trial to incorporate an administrator web system that enabled clinicians to monitor adherence and performance data in real time, facilitating a feedback loop between patients and health care providers. It demonstrated the potential of the app as a foundation for a medical information-sharing platform to support patient referrals and transfers. Fourth, this was the first cost-utility analysis of smartphone-based pulmonary rehabilitation conducted in Korea, which may provide health economic evidence to support potential coverage under the National Health Insurance system. Clinically, this integrated digital rehabilitation model can complement or substitute traditional center-based rehabilitation, expanding access for older adults and patients with limited mobility. Together, these innovations demonstrate a practical and evidence-based framework for integrating smartphone-based pulmonary rehabilitation into routine clinical and public health practice.

    This study has several limitations. First, while participants showed significant improvements in physical activity according to the IPAQ questionnaire, their correlations to objective measurements are limited [,]. Participants’ follow-up VO2 max was also lower than that at baseline. Many follow-up tests occurred during a particularly hot summer, which limited participants’ maximal exercise capacity during cardiopulmonary tests, especially as they had outpatient visits scheduled immediately afterward. Additionally, some participants, having experienced fatigue during the baseline test, did not reach their maximal exercise capacity at follow-up. In the control group, 2 participants underwent the 6-minute walk test instead of the cardiopulmonary exercise test due to severely impaired lung function, in accordance with the study protocol. The IPAQ questionnaire was administered during the cardiopulmonary exercise test, so these values were missing for those 2 participants. Although some missing data (IPAQ and DLCO) were observed at the follow-up time point, the Little’s test indicated that these data were missing at random. During the feasibility trial, we also noted that participants’ 6-minute walk distance increased by only 5 m after the rehabilitation. Future studies should develop a more refined exercise test protocol to address these challenges. Second, this study did not show statistically significant improvement in the EQ-5D-5L and HINT-8 indices. Studies with larger samples may reveal quality-of-life improvements for patients with chronic respiratory diseases. Third, this study found no improvement in hand grip strength or limb muscle mass in the intervention group, despite providing muscle exercises and nutritional supplements. Although we provided protein supplements of 10 g/day, this amount was far below the recommended daily protein intake for adults of 0.8-1.2 g/kg, so we believe the observed benefits were mainly driven by the app design itself. Future research should consider more tailored exercise programs and nutritional support to enhance physical parameters. Finally, due to several practical constraints, we were unable to set the control group as traditional face-to-face (center-based) pulmonary rehabilitation, which warrants caution when interpreting the findings of this study.

    Conclusions

    In the randomized controlled trial, the smartphone-based pulmonary rehabilitation program improved clinical outcomes, including quality of life, physical activity, and dyspnea, in patients with chronic respiratory diseases. Although physically active and program-compliant participants showed significant clinical improvements, the fact that fewer than half of the participants demonstrated good compliance highlights the need for more robust strategies to enhance adherence in future programs. Additionally, while our feasibility trial demonstrated the potential for rehabilitation programs for older adults with chronic respiratory diseases to be implemented in primary health care settings, further research and development will be necessary to achieve this in practice.

    This research was supported by a grant from the Korea Health Promotion R&D Project, funded by the Ministry of Health & Welfare, Republic of Korea (HS21C0096), a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT; RS-2023-NR077159), the Bio&Medical Technology Development Program of the NRF funded by the MSIT (RS-2022-NR067421 and RS-2023-00222687), and the National Institute of Health research project (2024ER080601). The funder had no involvement in the study design, data collection, analysis, interpretation, or the writing of the manuscript.

    The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.

    CC, A-RK, D-YK, SK, JO, HJK, BP, SHL, DK, HK, M-WJ, and SWL contributed to the planning of the study. SWL secured the funding for the study. CC, A-RK, D-YK, SK, DK, HK, SHL, M-WJ, and SWL conceived and designed the study. CC, M-WJ, and SWL collected the data and conducted data analysis. CC, M-WJ, and SWL interpreted the data and drafted the manuscript. All authors revised and approved the final version of the manuscript, and all take responsibility for its accuracy. Generative artificial intelligence was not used in any portion of the manuscript writing.

    None declared.

    Edited by S Brini, A Mavragani; submitted 30.Apr.2025; peer-reviewed by P O’Halloran, YC Liu; comments to author 03.Sep.2025; revised version received 19.Oct.2025; accepted 19.Oct.2025; published 28.Nov.2025.

    ©Chiwook Chung, Ah-Ram Kim, Do-Yoon Kang, Sunmok Kim, Jinyoung Oh, Hui Jung Kim, Byongjo Park, Seong Ho Lee, Dongbum Kim, Hee Kwon, Min-Woo Jo, Sei Won Lee. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 28.Nov.2025.

    This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research (ISSN 1438-8871), is properly cited. The complete bibliographic information, a link to the original publication on https://www.jmir.org/, as well as this copyright and license information must be included.

    Continue Reading

  • India’s Adani seeks up to $5 billion investment in Google data center to join AI boom

    India’s Adani seeks up to $5 billion investment in Google data center to join AI boom

    Nov 28 (Reuters) – India’s Adani Group plans to invest up to $5 billion in Alphabet-owned Google’s (GOOGL.O), opens new tab India AI data centre project, an executive said on Friday, as it seeks to cash in on booming demand for data capacity in the world’s most populous nation.
    In October, Google said it would invest $15 billion over five years to set up an artificial intelligence data centre in the southern state of Andhra Pradesh, its biggest investment in India.

    Sign up here.

    AI requires enormous computing power, pushing demand for specialised data centres that enable thousands of chips to be linked in clusters.

    Adani Group CFO Jugeshinder Singh said the Google project could mean an investment of up to $5 billion for Adani Connex – a joint venture between Adani Enterprises (ADEL.NS), opens new tab and private data centre operator EdgeConneX.

    “It’s not just Google, there are a lot of parties that would like to work with us, especially when the data centre capacity goes to gigawatt and higher,” Singh told reporters on Friday.

    Google has committed to spending about $85 billion this year to expand data centre capacity as tech companies invest heavily in infrastructure to meet the booming demand for AI services.

    Indian billionaires Gautam Adani and Mukesh Ambani have also unveiled investments in building data centre capacity.

    The data centre campus in the port city of Visakhapatnam will have an initial power capacity of 1 gigawatt.

    ($1 = 89.3660 Indian rupees)

    Reporting by Harshita Meenaktshi and Dhwani Pandya; Editing by Kevin Liffey

    Our Standards: The Thomson Reuters Trust Principles., opens new tab

    Continue Reading

  • India’s Adani seeks up to $5 billion investment in Google data center to join AI boom

    India’s Adani seeks up to $5 billion investment in Google data center to join AI boom

    (Reuters) -India’s Adani Group plans to invest up to $5 billion in Alphabet-owned ​Google’s India AI data centre project, an executive ‌said on Friday, as it seeks to cash in on booming demand ‌for data capacity in the world’s most populous nation.

    In October, Google said it would invest $15 billion over five years to set up an artificial intelligence data centre in the southern state ⁠of Andhra Pradesh, its ‌biggest investment in India.

    AI requires enormous computing power, pushing demand for specialised data centres that enable ‍thousands of chips to be linked in clusters.

    Adani Group CFO Jugeshinder Singh said the Google project could mean an investment of up to $5 billion ​for Adani Connex – a joint venture between Adani ‌Enterprises and private data centre operator EdgeConneX.

    “It’s not just Google, there are a lot of parties that would like to work with us, especially when the data centre capacity goes to gigawatt and higher,” Singh told reporters on ⁠Friday.

    Google has committed to spending about $85 ​billion this year to expand data ​centre capacity as tech companies invest heavily in infrastructure to meet the booming demand for AI services.

    Indian billionaires ‍Gautam Adani and ⁠Mukesh Ambani have also unveiled investments in building data centre capacity.

    The data centre campus in the port city of Visakhapatnam ⁠will have an initial power capacity of 1 gigawatt.

    ($1 = 89.3660 ‌Indian rupees)

    (Reporting by Harshita Meenaktshi and Dhwani ‌Pandya; Editing by Kevin Liffey)

    Continue Reading

  • Abu Dhabi’s TII and Honeywell Team to Advance Quantum-Secure Satellite Technology

    Abu Dhabi’s TII and Honeywell Team to Advance Quantum-Secure Satellite Technology

    Insider Brief

    • Abu Dhabi’s TII and Honeywell are collaborating to develop quantum-secure satellite communication systems using quantum key distribution technology.
    • The partnership integrates Honeywell’s QKDSat platform with TII’s Abu Dhabi Quantum Optical Ground Station to test end-to-end satellite-to-ground QKD links.
    • The initiative aims to build global quantum-resilient networks for government, security, and commercial use as traditional encryption faces quantum threats.

    PRESS RELEASE — The Technology Innovation Institute (TII), the applied research arm of Abu Dhabi’s Advanced Technology Research Council (ATRC), and Honeywell have launched a joint initiative to develop quantum-secure satellite communication systems designed to protect sensitive information across global networks.

    As quantum computing capabilities continue to evolve, traditional encryption methods are coming under increasing pressure. Quantum key distribution (QKD) offers a future-proof solution by using the quantum properties of light to generate encryption keys that are inherently immune to interception and secure against emerging computing threats.

    Under this collaboration, Honeywell’s ‘QKDSat’ platform will be integrated with TII’s ground-based infrastructure – the Abu Dhabi Quantum Optical Ground Station (ADQOGS) – to establish and test end-to-end QKD links between satellites and terrestrial quantum networks. The initiative represents a key step toward building quantum-resilient communication infrastructure capable of safeguarding critical data for government, security, and commercial applications.

    Dr. Najwa Aaraj, CEO of TII, said: “This collaboration is a significant step toward building global quantum-secure networks in the UAE and beyond. It brings together Honeywell’s track record in aerospace innovation and TII’s expertise in quantum technologies to address one of the most pressing challenges of the digital era: how we protect our most critical information in a quantum-powered future.”

    Quantum-resilient infrastructure said: “Turning quantum science into operational capability requires proven space engineering. Honeywell’s heritage in secure satellite systems allows us to take these concepts from laboratory testing to real-world missions. Teaming up with TII ensures that together we’re advancing technologies that can deliver trusted, quantum-secure communications on a global scale.”

    Developed and operated by TII, ADQOGS is a versatile optical ground station designed to support a range of satellite-based quantum communication experiments – methods used to encode information onto particles of light so they can transmit encryption keys securely between space and Earth. Its integration with Honeywell’s QKDSat platform will allow experts to test and validate quantum-backed encryption methods under realistic satellite operating conditions, demonstrating long-distance QKD links and overcoming the distance limitations of fiber-based quantum networks – opening the door to truly global quantum communication that is not constrained by terrestrial infrastructure.

    The collaboration underscores both organizations’ commitment to developing trusted, quantum-secure communication systems, and highlights Abu Dhabi’s growing role in shaping the future of global cybersecurity innovation.

    For more information about ADQOGS, visit https://www.tii.ae/publications/adqogs-versatile-optical-ground-station-satellite-based-quantum-key-distribution.

    For more information about QKDSat, visit https://aerospace.honeywell.com/us/en/products-and-services/product/services/quantum

    Continue Reading

  • Canadian Economy Rebounds by More Than Expected – The Wall Street Journal

    1. Canadian Economy Rebounds by More Than Expected  The Wall Street Journal
    2. Canada’s third-quarter annualised GDP surprises with growth of 2.6 percent  Al Jazeera
    3. Canada’s job growth to be flat in November, unemployment rate unchanged  RBC
    4. Canada dodged a technical recession. Here’s why everyone isn’t celebrating  Yahoo News Canada
    5. EUR/CAD falls as Canadian GDP beats expectations, Euro struggles with mixed data  FXStreet

    Continue Reading

  • Apple’s Ads, Maps Face EU Gatekeeper Test

    Apple’s Ads, Maps Face EU Gatekeeper Test

    This article first appeared on GuruFocus.

    Apple (NASDAQ:AAPL) just put two of its own services under Europe’s microscope, telling regulators that Apple Ads and Apple Maps now meet the thresholds set by the EU’s Digital Markets Act.

    That disclosure kicks off a formal review by the European Commission, which now has 45 working days to decide whether to label either service a gatekeeper. If that happens, Apple would get 6 months to comply with rules designed to make markets more open and easier for users to switch services.

    Apple is already pouring cold water on the idea that it wields real market power here. The company told Reuters its ad business is small in Europe compared with Google, Meta, and Microsoft. And when it comes to maps, Apple says its usage trails far behind services like Google Maps and Waze.

    The gatekeeper label brings heavier oversight and tighter rules. Bottom line is that Apple says it qualifies on paper, not in practice, and now Brussels decides what comes next.

    Continue Reading

  • Intel (INTC) Stock Jumps Amid Allegations of Stolen Tech from TSMC

    Intel (INTC) Stock Jumps Amid Allegations of Stolen Tech from TSMC

    This article first appeared on GuruFocus.

    Intel (NASDAQ:INTC) climbed about 8% at Thursday’s open, despite news that Taiwanese authorities searched the home of its executive Wei-Jen Lo. Officials are investigating whether Lo, formerly of Taiwan Semiconductor (NYSE:TSM), may have taken sensitive technology related to advanced semiconductor processes.

    During the raid, prosecutors seized computers and other materials. A court order also froze some of Lo’s assets, including real estate, as part of the inquiry. Taiwan Semiconductor (NYSE:TSM) has launched legal action, claiming Lo violated non-compete agreements and trade secrets regulations before leaving the company.

    Lo joined Intel (NASDAQ:INTC) as vice president of research and development after retiring from Taiwan Semiconductor (NYSE:TSM) in July, where he held a senior role in corporate strategy and advanced node technology development.

    Intel CEO Lip-Bu Tan rejected the allegations, telling Bloomberg they are speculation and emphasizing the company’s commitment to intellectual property rights.

    The investigation comes as Intel (NASDAQ:INTC) navigates new risks tied to a recent $11.1 billion U.S. government stake, highlighting the company’s ongoing challenges in global semiconductor expansion.

    On the positive side, analyst Ming-Chi Kuo said Apple (AAPL) is closer to choosing Intel as a foundry partner, boosting optimism around Intel’s 18A process and future chip orders.

    The report suggested Apple has tested Intel’s design tools and is waiting for the next software release, raising investor expectations that Intel could secure a major foundry contract and strengthen its position in semiconductor manufacturing.

    Continue Reading

  • Dubai Air Show 2025: repeat business dominates with agreements covering 176 engines

    Dubai Air Show 2025: repeat business dominates with agreements covering 176 engines


    The following agreements were announced:


    Air Europa

    • 80 Trent XWB-84 powering 40 Airbus A350-900

    Ewen McDonald, Chief Customer Officer, Civil Aerospace at Rolls-Royce, said: “Air Europa is already a valued customer, so it’s extremely exciting to deepen that relationship as we welcome them into the Trent XWB family.

    “The continued popularity of the Airbus A350-900 powered by the Trent XWB-84 is important to us and we look forward to working with Air Europa as they embark on their fleet renewal.”

    AviLease

    • Joined our newly-launched LessorCare+ service

    Rob Watson, President, Civil Aerospace, said: “It’s testament to the quality of our offering and the strength of our partnerships that we are seeing AviLease come on board with LessorCare+ at Dubai. There’s clearly demand among lessors for even greater insights into their asset holdings and we’re in the best position to offer that through LessorCare+.”

    Rolls-Royce is investing £1 billion across our modern Trent engines to increase their durability by an average of 80%, with a significant portion being delivered in 2025. For the Trent 7000 the time on wing enhancement package has tripled time on wing in some cases, with a further up to 30% to come in 2026.

    Emirates

    • 16 Trent XWB-84 power 8 Airbus A350-900
    • Joining our global MRO network (Trent 900) in 2027

    Paul Keenan, Director – Commercial Aviation Aftermarket Operations, Rolls-Royce, said: “Today’s announcement marks another milestone in our journey to significantly increase our global MRO capacity and capability by 2030. Our global network combines a strong mix of Rolls-Royce owned facilities, joint ventures and strategic collaborations with industry partners. We are delighted to welcome Emirates to that mix ahead of the new facility opening in 2027.

    “The agreement will allow for additional capacity in the entire Rolls-Royce network and further reinforces our commitment to deliver both excellent products and services to our global customer base.”

    Ethiopian Airlines

    • 12 Trent XWB-84 powering 6 Airbus A350-900

    Eithad Airways

    • 30 Trent 7000 powering 15 Airbus A330 Neo
    • 14 Trent XWB-97 powering 7 Airbus A350-1000
    • 20 Trent XWB-97 powering 10 Airbus A350F freighters

    Rob Watson, President, Civil Aerospace at Rolls-Royce, said: “Our Middle Eastern customers continue to perform strongly on the global stage, and we are investing in our engines and services to match that ambition.

    “We’re excited to continue our long-term partnership with Etihad, driven by confidence in the Trent XWB-97, where our investment will double time on wing in Middle East environments from 2028.”

    Silk Way West Airlines

    • 4 Trent XWB-97 powering 2 Airbus A350F freighters

    The Trent 7000 is the latest addition to the Rolls-Royce Trent family of engines and exclusively powers the Airbus A330neo. After entering service at the end of 2018, the Trent 7000 has flown more than three million hours, delivering exceptional reliability, sustainable performance and proven versatility.

    The Trent XWB-84 is the best widebody engine in the world. It’s designed, engineered, and optimised specifically for the Airbus A350 – delivering the lowest fuel consumption of any widebody engine and chosen by the world’s most profitable airlines.

    The Trent XWB-97 has proven its reliability and durability over seven years of service and more than three million engine flying hours. It has received the first two of its three phases of durability enhancements, which are already delivering a 60% increase in time on wing. The third phase, which will enter service in 2028, will total a doubling of time on wing in challenging environments; and provide 50% improvement in benign conditions.



    Continue Reading

  • Canada’s third-quarter annualised GDP surprises with growth of 2.6 percent | Business and Economy News

    Canada’s third-quarter annualised GDP surprises with growth of 2.6 percent | Business and Economy News

    Canada’s economy grew at a much faster pace than expected in the third quarter as crude oil exports and government spending boosted economic activity, data shows, even as business investments and household consumption disappointed due to the lingering uncertainty over United States tariffs.

    Third-quarter annualised gross domestic product (GDP) grew 2.6 percent, Statistics Canada said on Friday, escaping what could have been a technical recession after a contraction in the previous quarter of a downwardly revised 1.8 percent.

    Recommended Stories

    list of 4 itemsend of list

    The data strengthened economists’ view that the Bank of Canada will not cut interest rates on December 10.

    The quarterly GDP reading is calculated based on income and expenditure, unlike the monthly GDP, which is derived from industrial output.

    The statistics agency said the third-quarter number could be subjected to a larger-than-normal revision in February because foreign merchandise trade data was not available due to the recent US government shutdown.

    Analysts polled by the Reuters news agency had forecast annualised growth of 0.5 percent in the third quarter and monthly GDP growth of 0.2 percent in September.

    On a month-over-month basis, the economy matched analysts’ predictions following a deceleration of an upwardly revised 0.1 percent in the prior month, StatsCan said, primarily driven by a 1.6 percent expansion in manufacturing output.

    However, an advance estimate showed GDP might decline by 0.3 percent in October, signalling a negative start to the fourth quarter.

    “Headline growth was flattered by a large drop in imports which masked underlying weakness in domestic demand as households and businesses spent less,” Tony Stillo, head of Canada Economics at Oxford Economics, and senior economist Michael Davenport, said in comments emailed to Al Jazeera.

    “We still think the Canadian economy is in a fragile position and expect it will struggle to grow in the near term amid US tariffs, elevated trade policy uncertainty, and much slower population growth.”

    Tariff hit

    US tariffs on critical sectors have hit Canadian exports hard. They have resulted in job losses, dampened hiring and subdued business and consumer sentiment, leading to forecasts of a near-recessionary environment.

    But a 6.7 percent increase in crude oil and bitumen exports, along with a 2.9 percent increase in government capital investments, helped cushion some of the impact, and higher crude oil exports also helped boost corporate income in the third quarter, StatsCan’s data showed.

    An increase in spending on weapon systems and nonresidential structures, such as hospitals, led the jump in government investments.

    A rise in residential resale activity and renovations also helped.

    The report “should quash recession chatter for now”, Doug Porter, chief economist at BMO Capital Markets, wrote in a note.

    The Bank of Canada said last month that it will keep its key interest rate on hold at 2.25 percent and take action only when there is a significant change in the economic outlook.

    The underlying impact of tariffs, however, continues to be reflected in business and consumer sentiment, the GDP data showed.

    Business capital investment was unchanged in the third quarter, and household final consumption expenditure dropped 0.1 percent.

    New residential construction also declined 0.8 percent in the period, StatsCan added.

    “Overall final domestic demand was flat in Q3, so the stronger-than-expected rebound in headline GDP more so reflects a mathematical boost from falling imports rather than underlying economic strength,” warned Stillo and Davenport.

    Continue Reading

  • El Jannah Announces Restaurant Expansion Plan and Financial  Investment From General Atlantic

    El Jannah Announces Restaurant Expansion Plan and Financial  Investment From General Atlantic

    Accelerating a Great Australian Family Story

    One of Australia’s premium charcoal chicken brands, El Jannah, today announced a  bold national expansion strategy to quadruple its number of restaurants from 50 to  almost 200 in the coming years. 

    From a humble charcoal chicken shop opened by Lebanese migrant couple Andre and  Carole Estephan in Western Sydney in 1998, El Jannah has quickly developed into an  Australian cultural institution. 

    Serving charcoal-grilled chicken platters with family hospitality and warmth, El Jannah  has built a loyal and growing base of customers across Australia, with a reputation for  serving fresh, high-quality and affordable food. 

    Since 2020, El Jannah has grown its number of restaurants from five to 50, with 160,000  transactions occuring every week across Sydney, Melbourne, Canberra, Wollongong  and the Southern Highlands. 

    Mr Estephan said his dream was for millions of Australians to be able to enjoy El  Jannah’s unique Middle Eastern chicken offering for the first time. 

    “From the day Carole and I opened our first restaurant in Granville, our dream was  simple — to share the flavours and hospitality we grew up with in Lebanon,” he said. 

    “We built El Jannah with our family for Australian families. We now want to carry that  dream into its next generation, while keeping our culture, values and identity exactly  where they belong — at the heart of the business. 

    “Our dream is to offer our customers more locations and more convenience, allowing  more people to discover the brand Australians already love. We want to share our authentic flavours and recipes, our renowned service reflecting Lebanese warmth and  our cultural soul that has defined us from the beginning.” 

    As part of its next growth chapter, El Jannah intends to open more than 25 restaurants in  the following locations in the next 12 months: 

    • NSW – Cranebrook, Cronulla, Emerald Hills, Maroubra, North Rocks, Ropes  Crossing, Rozelle, Rutherford (Hunter Valley), Sydney CBD and Warringah Mall.
    • Victoria – Armstrong Creek, Ashburton, Box Hill, Carrum Downs, Corio,  Cranbourne East, Cranbourne West, Hawthorn, Ivanhoe, Lilydale, Roxburgh  Park, South Yarra, Sunbury, Wollert and Wyndam Vale. 
    • ACT – Woden. 

    The brand’s future growth is being made possible because of a significant investment  from General Atlantic, a leading global investor.  

    Founded in 1980, General Atlantic specialises in partnering with innovative businesses  around the world. General Atlantic has a strong track record of supporting founders and  management teams to accelerate growth, including through domestic and international  expansion and development of digital capabilities. 

    General Atlantic has invested in a range of high-growth food and beverage companies  globally, including Joe & The Juice, as well as distinguished Australian brand  Zimmermann. 

    El Jannah CEO Brett Houldin will continue to lead the business, supported by the  Estephan family and General Atlantic. 

    Mr Houldin said the company’s signature charcoal chicken, its unmistakable garlic  sauce, and the warmth of Lebanese family hospitality were part of its soul and DNA  created by the Estephans. 

    “Our partnership with GA means we can explore selective international expansion for  the first time, including the possibility of exporting our unique Australian-Middle Eastern  flavour profile back to the Middle East, and into other high-potential markets,” he said. 

    “That will be the ultimate proof of the Australian migrant success story. We are  committed to preserving the soul of the brand the Estephan family built, while  accelerating our next phase of growth. With General Atlantic beside us, we are  positioned to grow our Australian footprint, deepen our digital and guest experience  capability, and explore selective international opportunities.” 

    Neal Kok, Managing Director and Head of Southeast Asia & Australia at General Atlantic, said: “El Jannah is one of the most distinctive and exciting restaurant offerings we have  seen in Australia. Its combination of authentic food and amazing community following  are core to what has made it an incredible success. We are privileged to support the business in its next leg of expansion and proud to partner with Brett and the Estephan  family as they bring El Jannah to more communities across Australia and, in time,  internationally.” 

    Media enquiries: 

    El Jannah  

    Adam Connolly, Apollo Communications, +61 (0)417 710 084 

    General Atlantic 

    Jess Gill [email protected]
    Scott Schuberg [email protected]
    Jonathan Buxeda [email protected] 

    About El Jannah 

    El Jannah is a family-owned Lebanese-Australian restaurant brand renowned for its  legendary charcoal chicken and famous garlic sauce. Founded in 1998 in Granville,  Sydney, by Andre and Carole Estephan, the business has grown from a humble  neighbourhood eatery in western Sydney into one of Australia’s most beloved restaurant  brands. Today, El Jannah is celebrated for its Lebanese hospitality with generous  portions, fresh ingredients, and commitment to bringing people together over authentic,  shareable food. With 50 locations expanding across the country, El Jannah continues to  uphold its family values and heritage while delivering a unique dining experience to  generations of loyal fans. 

    About General Atlantic 

    General Atlantic is a leading global investor with more than four and a half decades of  experience providing capital and strategic support for over 830 companies throughout  its history. Established in 1980, General Atlantic continues to be a dedicated partner to  visionary founders and investors seeking to build dynamic businesses and create long term value. Guided by the conviction that entrepreneurs can be incredible agents of  transformational change, the firm combines a collaborative global approach, sector specific expertise, a long-term investment horizon, and a deep understanding of growth  drivers to partner with and scale innovative businesses around the world. The firm  leverages its patient capital, operational expertise, and global platform to support a  diversified investment platform spanning Growth Equity, Credit, Climate, and  Sustainable Infrastructure strategies. General Atlantic manages approximately $118 billion in assets under management, inclusive of all strategies, as of September 30,  2025, with more than 900 professionals in 20 countries across five regions. For more  information on General Atlantic, please visit: www.generalatlantic.com.

    Continue Reading